Ethical use of off-label disease-modifying therapies for multiple sclerosis
Joanna Laurson-Doube(Multiple Sclerosis International Federation), Bassem Yamout(American University of Beirut Medical Center), Nick Rijke(Multiple Sclerosis International Federation), Anne Helme(Multiple Sclerosis International Federation), Bernhard Hemmer(TUM Klinikum), Shanthi Viswanathan(Children's Hospital Research Institute of Manitoba), Brenda Banwell(University of Toronto), Peer Baneke(Multiple Sclerosis International Federation)
Cited by 28
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
|Neurology|2015|4.6k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
|Multiple Sclerosis Journal|2020|2.5k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k